Delivering Therapeutics Across Biological Barriers Organizer(s): David Brayden, Claus-Michael Lehr and Kathryn Whitehead Date: May 06 - 09, 2019 Location: Royal Dublin Society, Dublin 4, IrelandThe multi-disciplinary theme of crossing of biological barriers encompasses biology, chemistry, pharmaceutical formulation, polymeric and materials science, advanced cell biology, imaging, microfluidics, and drug-device combination research. This conference occurs at the interface between cell biology and the use of technologies to exploit such understanding in order to translate therapies to patients. The program comprises leading researchers from academia, institutes, as well as from the pharmaceutical and medical device industry. The goal of the conference is to profile cutting edge research in specific areas of achieving drug delivery across biological barriers where a large translational impact would result for both industry and patients. By inviting cell biologists, technology developers, and formulators to the same conference, this will provide in depth discussions and offer a thorough perspective on the tissue and cell barriers that must be crossed in order to help guide technology approaches to achieve these breakthrough treatments. Scholarship Deadline: January 8 2019 Discounted Abstract Deadline: January 8 2019 Abstract Deadline: February 6 2019 Discounted Registration Deadline: March 6 2019 We gratefully acknowledge additional support for this conference from:   We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
AstraZeneca
We gratefully acknowledge the generous grant for this conference provided by: National Institute of Biomedical Imaging and Bioengineering (NIBIB)Grant No. 1R13EB028133-01 Funding for this conference was made possible (in part) by 1R13EB028133-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. |